Brief: Ose Immunotherapeutics Presents First Positive Clinical Results With Its anti-PD1 OSE-279 In Advanced Solid Tumors
16/10/2023 06:57
Oct 16 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS PRESENTS FIRST POSITIVE CLINICAL
RESULTS
WITH ITS ANTI-PD1 OSE-279 IN ADVANCED SOLID TUMORS
* COMMUNICATION REPORTED ON FIRST POSITIVE RESULTS FROM
PHASE 1/2
CLINICAL TRIAL EVALUATING OSE-279 MONOTHERAPY IN PATIENTS WITH
ADVANCED SOLID TUMORS, WITH NO THERAPEUTIC OPTION AVAILABLE
Source text for Eikon: ID:nBw4srl28a
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO